EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative Efficacy of Aldosterone‐Related Sodium‐Retention Pathway Therapies for Resistant Hypertension: A Drug‐Level Network Meta‐Analysis of Randomized Controlled Trials

Yi-Liang Tsou, Yu-Hung Wang, Yi-Siou Lin, Chia-Liang Chen

The Journal of Clinical Hypertension · 2026-09 · 28 (9)

DOI: 10.1111/jch.70365 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 18.09.2026. Verfasst von Yi-Liang Tsou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. Hauptthemen laut MEDLINE: Hypertension, Mineralocorticoid Receptor Antagonists, Aldosterone, Antihypertensive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mineralocorticoid receptor antagonists (MRAs), aldosterone synthase inhibitors (ASIs), and epithelial sodium channel (ENaC) blockade target different levels of the aldosterone‐related sodium‐retention pathway in resistant hypertension (RH), but the comparative efficacy of individual agents remains uncertain. We conducted a focused drug‐level network meta‐analysis of randomized controlled trials (RCTs) comparing pathway‐directed therapies in adults with RH. PubMed, Scopus, Embase, Cochrane CENTRAL, Cochrane Reviews, and ClinicalTrials.gov were searched from inception to July 20, 2026. The primary outcome was change in office systolic blood pressure (BP). Secondary outcomes included office diastolic BP and 24‐hour ambulatory systolic and diastolic BP. Ten RCTs including 2865 participants were analyzed. In the primary drug‐level analysis, amiloride, spironolactone, baxdrostat, eplerenone, and lorundrostat significantly reduced office systolic BP compared with placebo, with mean differences (MDs) of −14.08, −10.78, −9.09, −8.14, and −6.80 mmHg, respectively. Osilodrostat showed a statistically uncertain effect, with an MD of −2.61 mmHg. At the class level, both MRAs and ASIs showed clinically meaningful reductions in office systolic BP. Secondary outcomes were generally consistent with the primary analysis, although fewer trials contributed to these networks. Sensitivity analyses did not materially change the primary findings. These results support the aldosterone‐related sodium‐retention pathway as an important therapeutic target in RH. MRAs remain the established reference add‐on therapy, whereas newer ASIs and amiloride may represent pathway‐based alternatives for selected patients. Trial Registration : INPLASY202670099

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionMineralocorticoid Receptor AntagonistsAldosteroneAntihypertensive AgentsHumansRandomized Controlled Trials as TopicBlood PressureEpithelial Sodium Channel BlockersCytochrome P-450 CYP11B2SodiumTreatment OutcomeAmilorideSpironolactoneBlood Pressure Monitoring, Ambulatory

Substanzen

Mineralocorticoid Receptor AntagonistsAldosteroneAntihypertensive AgentsEpithelial Sodium Channel BlockersCytochrome P-450 CYP11B2SodiumAmilorideSpironolactone

Autor:innen und Institutionen

  • Heart Failure Research Center, Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.

Zitieren

APA

Tsou, Y. L., Wang, Y. H., Lin, Y. S., & Chen, C. L. (2026). Comparative Efficacy of Aldosterone‐Related Sodium‐Retention Pathway Therapies for Resistant Hypertension: A Drug‐Level Network Meta‐Analysis of Randomized Controlled Trials. The Journal of Clinical Hypertension, 28(9). https://doi.org/10.1111/jch.70365

Vancouver

Tsou YL, Wang YH, Lin YS, Chen CL. Comparative Efficacy of Aldosterone‐Related Sodium‐Retention Pathway Therapies for Resistant Hypertension: A Drug‐Level Network Meta‐Analysis of Randomized Controlled Trials. The Journal of Clinical Hypertension. 2026;28(9). doi:10.1111/jch.70365

BibTeX
@article{Tsou2026,
  author = {Tsou, Yi-Liang and Wang, Yu-Hung and Lin, Yi-Siou and Chen, Chia-Liang},
  title = {Comparative Efficacy of Aldosterone‐Related Sodium‐Retention Pathway Therapies for Resistant Hypertension: A Drug‐Level Network Meta‐Analysis of Randomized Controlled Trials},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  volume = {28},
  number = {9},
  doi = {10.1111/jch.70365}
}
Kostenlos starten →